Tyrosine metabolic pathway

The tyrosine metabolic pathway is a series of biochemical reactions responsible for the catabolism and transformation of the amino acid tyrosine into a variety of biologically important molecules. Tyrosine metabolism generates key neurotransmitters (such as dopamine, norepinephrine, and epinephrine), thyroid hormones (thyroxine and triiodothyronine), melanin pigment, and energy intermediates (fumarate, acetoacetate)[3][5][8]. The pathway initiates with the transamination of tyrosine via tyrosine aminotransferase (TAT) to 4-hydroxyphenylpyruvate, followed by a cascade of enzyme reactions that differ depending on the tissue context and physiological demands[1][3]. Dysregulation of enzymes in this pathway leads to inborn errors of metabolism (for example, tyrosinemia), and has been implicated in cancer progression, particularly in tumors with altered metabolic profiles such as glioblastomas and hepatocellular carcinoma[2][4][8]. While individual enzymes (e.g., TAT, HPD, MAOA) are considered therapeutic targets, the tyrosine metabolic pathway as a whole is a biological process, not a single molecular target. Metabolic interventions—such as enzyme inhibitors (disulfiram for ALDH) or metabolic modulators (metformin)—are being investigated for therapeutic benefit, especially in oncology[4]. Measurement of tyrosine, its metabolites, and enzyme levels in this pathway serves as important biomarkers for disease diagnosis, therapy monitoring, and patient stratification[1][2][4]. Because the pathway comprises multiple enzymes and metabolites, references to "tyrosine metabolic pathway" are overly broad for the purposes of molecular targeting and should be replaced with specific enzymes or transporters within the pathway when defining drug targets.

Other names

Tyrosine metabolismTyrosine catabolismTyrosine biosynthetic pathway

Inhibition of metabolic pathway enzymes (e.g., inhibition of ALDH, AMPK activation by metformin); Substrate supplementation (e.g., L-DOPA as dopamine precursor)